TrialThe Lancet. Respiratory medicine2023

Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fengcai Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.